NeuACT, a Phase II trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer

Summary of SUO 2013 poster, "NeuACT, a Phase 2 Randomized, Open-label Trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer: Updated Analysis of Product Parameters, HER2 Expression and Safety"

Leonard G. Gomella, MD, FACS
Thomas Jefferson University Hospital

Click HERE to read the abstract and view the poster

Click HERE to read a report from this session by the Fox Chase Cancer Center team